JONATHAN BRAUN, MD
Medical Practice at Le Conte Ave, Los Angeles, CA
License number
California G51811
Category
Medical Practice
Type
Anatomic Pathology & Clinical Pathology
License number
California G51811
Category
Medical Practice
Type
Immunopathology
Address
Address
10833 Le Conte Ave, Los Angeles, CA 90095
Phone
(310) 794-8285
Personal information
See more information about JONATHAN BRAUN at radaris.comName
Address
Phone
6762 Pasado Rd #B, Goleta, CA 93117
PO Box 627, San Anselmo, CA 94979
1453 S Crest Dr, Los Angeles, CA 90035
25717 Turquesa Dr, Valencia, CA 91355
3924 Hilton Head Way, Tarzana, CA 91356
Organization information
See more information about JONATHAN BRAUN at bizstanding.comThe Braun/Gordon Living Trust, Dated 12/26/90, Jonathan Braun and Lynn K Gordon, Co-Trustees
3924 Hilton Head Way, Los Angeles, CA 91356
Status:
Inactive
Member:
Gordon Braun Enterprises, L.p (Member)
Professional information
Dr. Jonathan Braun, Los Angeles CA - MD (Doctor of Medicine)
Specialties:
Anatomic Pathology
Address:
924 Westwood Blvd, Los Angeles 90024
(310) 794-8285 (Phone)
(310) 794-8285 (Phone)
Languages:
English
Hospitals:
924 Westwood Blvd, Los Angeles 90024
Ronald Reagan UCLA Medical Center
757 Westwood Plz, Los Angeles 90095
Ronald Reagan UCLA Medical Center
757 Westwood Plz, Los Angeles 90095
Education:
Medical School
Harvard Medical School
Graduated: 1981
Brigham and Women's Hospital
Harvard Medical School
Graduated: 1981
Brigham and Women's Hospital
Ibd-Associated Microbial Nucleic Acid Molecules
US Patent:
6759530, Jul 6, 2004
Filed:
Sep 27, 2001
Appl. No.:
09/966608
Inventors:
Jonathan Braun - Tarzana CA
Christopher Sutton - Encinitas CA
Christopher Sutton - Encinitas CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C07H 2104
US Classification:
536 2432, 536 237, 4241901
Abstract:
The present invention provides nucleic acid and amino acid sequence of the novel I-1 and I-2 polypeptides, which are associated with human inflammatory bowel disease (IBD). Methods of diagnosing and treating inflammatory bowel disease using the IBD-associated I-1 and I-2 antigens also are provided.
Jonathan Braun, Los Angeles CA
Specialties:
Pathologist
Address:
10833 Le Conte Ave, Los Angeles, CA 90095
Genotoxicity As A Biomarker For Inflammation
US Patent:
8445200, May 21, 2013
Filed:
Apr 15, 2010
Appl. No.:
12/761330
Inventors:
Aya M. Westbrook - Cypress CA, US
Robert H. Schiestl - Encino CA, US
Bo Wei - Rancho Palos Verdes CA, US
Jonathan Braun - Tarzana CA, US
Robert H. Schiestl - Encino CA, US
Bo Wei - Rancho Palos Verdes CA, US
Jonathan Braun - Tarzana CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12Q 1/68
US Classification:
435 61
Abstract:
The invention provides a method for detection of inflammatory disease in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of DNA damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammatory disease activity, including sub-clinical inflammation. The method can be adapted for quantitatively monitoring the efficacy of treatment of inflammatory disease in a subject. Markers of DNA damage include single- and/or double-stranded breaks in leukocytes, oxidative DNA damage in leukocytes, or a marker of nitric oxide oxidative activity (protein nitrosylation in leukocytes). The inflammatory disease can be inflammatory bowel disease (ulcerative colitis or Crohn's disease). The invention may also be used for detection of other types of inflammatory disease, such as non-immune intestinal inflammatory disease (diverticulitis, pseudomembranous colitis), autoimmune diseases (rheumatoid arthritis, lupus, multiple sclerosis, psoriasis, uveitis, vasculitis), or non-immune lung diseases (asthma, chronic obstructive lung disease, and interstitial pneumonitis). This unexpected discovery of markers of genotoxicity present in circulating leukocytes enables detection of inflammation occurring at a localized site with a relatively simple and minimally invasive assay using peripheral blood.
Epithelial Membrane Protein 2 (Emp2) Binding Reagents And Their Therapeutic Uses In Ocular Diseases
US Patent:
2013003, Feb 7, 2013
Filed:
Feb 22, 2011
Appl. No.:
13/580100
Inventors:
Lynn K. Gordon - Tarzana CA, US
Jonathan Braun - Tarzana CA, US
Shawn A. Morales - Pasadena CA, US
David Telander - Carmichael CA, US
Madhuri Wadehra - Manhattan Beach CA, US
Jonathan Braun - Tarzana CA, US
Shawn A. Morales - Pasadena CA, US
David Telander - Carmichael CA, US
Madhuri Wadehra - Manhattan Beach CA, US
Assignee:
United States Government Department of Veterans Affairs - Washington DC
The Regents of the University of California - Oakland CA
The Regents of the University of California - Oakland CA
International Classification:
A61K 39/395, A61P 27/02, A61K 31/7088
US Classification:
4241351, 4241721, 514 44 A
Abstract:
A method is disclosed for treating diseases or disorders of the eye involving undesired expression of vascular endothelial growth factor (VEGF) by administration of endothelial membrane protein 2 (EMP2) inhibitor. The present invention relates to the direct treatment of macular degeneration, particularly age-related macular degeneration (AMD), by administering an EMP2 inhibitor intraocularly or systemically.
Diagnosis, Prevention And Treatment Of Crohn's Disease Using The Ompc Antigen
US Patent:
7138237, Nov 21, 2006
Filed:
May 19, 2000
Appl. No.:
09/575061
Inventors:
Stephan R. Targan - Santa Monica CA, US
Jonathan Braun - Tarzana CA, US
Christopher L. Sutton - Encinitas CA, US
Jonathan Braun - Tarzana CA, US
Christopher L. Sutton - Encinitas CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
The Regents of the University of California - Oakland CA
The Regents of the University of California - Oakland CA
International Classification:
G01N 33/53, G01N 33/563, G01N 33/564
US Classification:
435 71, 435 6, 435 72, 435 732, 435 737, 435849, 435965, 435973, 436506, 436513, 436517, 436811
Abstract:
The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence of IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease.
Methods Of Diagnosing And Characterizing Cannabinoid Signaling In Crohn's Disease
US Patent:
2011012, May 26, 2011
Filed:
May 20, 2009
Appl. No.:
12/993685
Inventors:
Stephan R. Targan - Santa Monica CA, US
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
David Ziring - Los Angeles CA, US
Jonathan Braun - Tarzana CA, US
Bo Wei - Rancho Palos Verdes CA, US
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
David Ziring - Los Angeles CA, US
Jonathan Braun - Tarzana CA, US
Bo Wei - Rancho Palos Verdes CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
A61K 31/5377, C12Q 1/68, A61P 1/00
US Classification:
5142352, 435 61
Abstract:
Diagnosis of Crohn's Disease by determining the presence or absence of variants at the CNR2 (cannabinoid) genetic locus and serological markers is disclosed Methods of diagnosing a Crohn's Disease sub-type by determining the presence or absence of one or more risk variants at the CNR2 5 locus and the presence or absence of ASCA, OmpC, 12 and/or anti-Cbir1 antibodies are included
Diagnosis, Prevention And Treatment Of Crohn's Disease Using The Ompc Antigen
US Patent:
7993866, Aug 9, 2011
Filed:
Jan 12, 2009
Appl. No.:
12/352578
Inventors:
Stephan R. Targan - Santa Monica CA, US
Jonathan Braun - Tarzana CA, US
Christopher L. Sutton - Encinitas CA, US
Jonathan Braun - Tarzana CA, US
Christopher L. Sutton - Encinitas CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
The Regents of the University of California - Oakland CA
The Regents of the University of California - Oakland CA
International Classification:
G01N 33/569, G01N 33/564
US Classification:
435 732, 435 4, 435 71, 435 72, 435 792, 4352872, 4352883, 436506, 436512, 436513, 436518, 436811, 422 73, 422 8205, 422 91, 422430
Abstract:
The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence or IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease.
Emp2 Antibodies And Their Therapeutic Uses
US Patent:
8318906, Nov 27, 2012
Filed:
Oct 8, 2008
Appl. No.:
12/682032
Inventors:
Jonathan Braun - Tarzana CA, US
Lynn K. Gordon - Tarzana CA, US
Kaori Shimizaki - Los Angeles CA, US
Kathy A. Kelly - Sherman Oaks CA, US
Anna M. Wu - Sherman Oaks CA, US
Lynn K. Gordon - Tarzana CA, US
Kaori Shimizaki - Los Angeles CA, US
Kathy A. Kelly - Sherman Oaks CA, US
Anna M. Wu - Sherman Oaks CA, US
Assignee:
The Regents of The University of California - Oakland CA
International Classification:
C07K 16/00, C12P 21/08, A61K 39/395, G01N 33/566
US Classification:
5303871, 4241581, 436501, 5303873, 5303881, 5303892
Abstract:
The present invention provides methods and compositions useful in the treatment or prevention of infections and cancer. The methods and compositions inhibit the entry of into a host cell expressing EMP2 by interfering with the interaction between the and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.
Antibody Materials For An Ibd-Associated Polypeptide
US Patent:
7557194, Jul 7, 2009
Filed:
Apr 30, 2004
Appl. No.:
10/835914
Inventors:
Jonathan Braun - Tarzana CA, US
Christopher Sutton - Encinitas CA, US
Christopher Sutton - Encinitas CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C07K 16/12
US Classification:
5303895, 5303884, 5303873
Abstract:
The present invention provides nucleic acid and amino acid sequence of the novel I-1 and I-2 polypeptides, which are associated with human inflammatory bowel disease (IBD). Methods of diagnosing and treating inflammatory bowel disease using the IBD-associated I-1 and I-2 antigens also are provided.